Highlights and Quick Summary
- Research and Development (R&D) Expenses Growth for the quarter ending September 30, 2022 was 5.54% (a -67.87% decrease compared to previous quarter)
- Year-over-year quarterly Research and Development (R&D) Expenses Growth decreased by -93.05%
- Annual Research and Development (R&D) Expenses Growth for 2021 was 69.81% (a 370.1% increase from previous year)
- Annual Research and Development (R&D) Expenses Growth for 2020 was 14.85% (a -43.17% decrease from previous year)
- Annual Research and Development (R&D) Expenses Growth for 2019 was 26.13% (a -2.39% decrease from previous year)
- Twelve month Research and Development (R&D) Expenses Growth ending September 30, 2022 was 34.87% (a -29.81% decrease compared to previous quarter)
- Twelve month trailing Research and Development (R&D) Expenses Growth decreased by -50.05% year-over-year
Trailing Research and Development (R&D) Expenses Growth for the last four month:
| 30 Sep '22 | 30 Jun '22 | 31 Mar '22 | 31 Dec '21 |
|---|---|---|---|
| 34.87% | 49.68% | 70.98% | 69.81% |
Visit stockrow.com/BCRX
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Research and Development (R&D) Expenses Growth of BioCryst Pharmaceuticals, Inc.
Most recent Research and Development (R&D) Expenses Growthof BCRX including historical data for past 10 years.Interactive Chart of Research and Development (R&D) Expenses Growth of BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. Research and Development (R&D) Expenses Growth for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2022 | – | 5.54% | 17.24% | 54.02% | – |
| 2021 | 79.69% | 65.22% | 92.28% | 42.08% | 69.81% |
| 2020 | 32.05% | 20.4% | -0.66% | 8.63% | 14.85% |
| 2019 | 14.27% | 14.15% | 31.75% | 49.09% | 26.13% |
| 2018 | 38.45% | 25.68% | 33.32% | 9.96% | 26.77% |
| 2017 | 39.2% | 24.13% | 11.25% | -18.51% | 9.76% |
| 2016 | -36.17% | -29.71% | -14.27% | 20.2% | -16.15% |
| 2015 | 2.9% | 53.94% | 49.31% | 86.43% | 40.47% |
| 2014 | 19.68% | 68.53% | -3.99% | 27.28% | 23.49% |
| 2013 | 76.03% | -35.93% | -9.78% | -53.53% | -14.68% |
| 2012 | -38.57% | -20.06% | -11.53% | 15.83% | -14.13% |
Business Profile of BioCryst Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology